Over the past two weeks, there's been a 6.3% jump in cases, according to the CDC. The past week saw an increase of 7.1% in test positivity. The news is a boon for Moderna, BioNTech and Novavax.

Novavax's vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on Ju Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein ...

The CDC ACIP recommends 2 doses of the 2024-2025 COVID-19 vaccine for those age 65+ years and 2 or more doses for immunocompromised individuals.

The most recent trading session ended with Novavax (NVAX) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6 ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable ...